## Kathryn Trinkaus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6619191/publications.pdf

Version: 2024-02-01

		687363	552781
35	693	13	26
papers	citations	h-index	g-index
35	35	35	1554
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 107-113.	2.0	8
2	Diffusion basis spectrum imaging provides insights into MS pathology. Neurology: Neuroimmunology and NeuroInflammation, 2020, $7$ , .	6.0	25
3	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine, 2020, 12, .	12.4	41
4	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncology, The, 2019, 20, 1295-1305.	10.7	87
5	Diffusion basis spectrum imaging for identifying pathologies in MS subtypes. Annals of Clinical and Translational Neurology, 2019, 6, 2323-2327.	3.7	17
6	Giving Voice to Black Men: Guidance for Increasing the Likelihood of Having a Usual Source of Care. American Journal of Men's Health, 2019, 13, 155798831985673.	1.6	6
7	Threat sensitivity is associated with the healthcare source used most often: doctor's office, emergency room, or none at all. Heliyon, 2019, 5, e01685.	3.2	0
8	Asymmetric sensorineural hearing loss is a risk factor for lateâ€onset hearing loss in pediatric cancer survivors following cisplatin treatment. Pediatric Blood and Cancer, 2019, 66, e27494.	1.5	8
9	Geriatric Assessment in Older Adults with Multiple Myeloma. Journal of the American Geriatrics Society, 2019, 67, 987-991.	2.6	42
10	Bone marrow dendritic cells regulate hematopoietic stem/progenitor cell trafficking. Journal of Clinical Investigation, 2019, 129, 2920-2931.	8.2	40
11	Intensity ratio to improve black hole assessment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 140-147.	2.0	11
12	Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 687-693.	2.0	5
13	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 2379-2380.	27.0	0
14	Fractional anisotropy to quantify cervical spondylotic myelopathy severity. Journal of Neurosurgical Sciences, 2018, 62, 406-412.	0.6	14
15	Second primary melanomas: Increased risk and decreased time to presentation in patients exposed to tanning beds. Journal of the American Academy of Dermatology, 2018, 79, 1101-1108.	1.2	5
16	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncology, The, 2018, 19, 1082-1093.	10.7	21
17	Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4203-4203.	1.4	0
18	A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 2146-2146.	1.4	0

#	Article	lF	Citations
19	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncology, 2017, 72, 26-31.	1.5	12
20	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica, 2016, 101, e465-e468.	3.5	54
21	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2016, 58, 41-48.	1.5	78
22	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncology, 2016, 61, 1-7.	1.5	18
23	Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant. Blood, 2016, 128, 3419-3419.	1.4	0
24	Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. Blood, 2016, 128, 4698-4698.	1.4	0
25	Paired-like Homeodomain Transcription factor 2 expression by breast cancer bone marrow disseminated tumor cells is associated with early recurrent disease development. Breast Cancer Research and Treatment, 2015, 153, 507-517.	2.5	10
26	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. Blood, 2015, 126, 3106-3106.	1.4	0
27	Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis. Neurobiology of Disease, 2014, 67, 1-8.	4.4	20
28	Quantifying white matter tract diffusion parameters in the presence of increased extra-fiber cellularity and vasogenic edema. NeuroImage, 2014, 101, 310-319.	4.2	108
29	Axonal transport rate decreased at the onset of optic neuritis in EAE mice. Neurolmage, 2014, 100, 244-253.	4.2	35
30	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2012, 120, 1623-1623.	1.4	7
31	High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability. Blood, 2012, 120, 4095-4095.	1.4	1
32	The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide. Blood, 2012, 120, 4050-4050.	1.4	0
33	Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 3127-3127.	1.4	0
34	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Blood, 2009, 114, 3693-3693.	1.4	12
35	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. Blood, 2008, 112, 2595-2595.	1.4	8

3